Suzanna Noy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Suzanna Noy has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth M. C. Fisher
Department of Neuromuscular Diseases, and UCL Queen Square Motor Neuron Disease Centre, UCL, Institute of Neurology, London, UK
2 shared publications - Abraham Acevedo-Arozena
Hospital Universitario de Canarias
1 shared publication Adrian M Isaacs
Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK
1 shared publication- Alan Mejia Maza
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
1 shared publication - Anny Devoy
United Kingdom Dementia Research Institute Centre at King's College London, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK
1 shared publication - Benjamin Davies
The Francis Crick Institute, London, UK
1 shared publication
Latest Publications
- Open Access
- 1 January 2020
- Published by Elsevier in Cell Reports
- Vol. 30 (4) , 1152-1163.e4
Altered Hippocampal-Prefrontal Neural Dynamics in Mouse Models of Down Syndrome
- 1 January 2020
- Published by Elsevier in Cell Reports
- Vol. 30 (4) , 1152-1163.e4
Open AccessAltered Hippocampal-Prefrontal Neural Dynamics in Mouse Models of Down Syndrome
- 1 July 2018
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 50, 26-37
T1, diffusion tensor, and quantitative magnetization transfer imaging of the hippocampus in an Alzheimer's disease mouse model
- 1 July 2018
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 50, 26-37
T1, diffusion tensor, and quantitative magnetization transfer imaging of the hippocampus in an Alzheimer's disease mouse model
- Open Access
- 7 October 2017
- Published by Oxford University Press (OUP) in Brain
- Vol. 140 (11) , 2797-2805
Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in ‘FUSDelta14’ knockin mice
Mutations in FUS are causative for amyotrophic lateral sclerosis with a dominant mode of inheritance. In trying to model FUS-amyotrophic lateral sclerosis (ALS) in mouse it is clear that FUS is dosage-sensitive and effects arise from overexpression per se in transgenic strains. Novel models are required that maintain physiological levels of FUS expression and that recapitulate the human disease—with progressive loss of motor neurons in heterozygous animals. Here, we describe a new humanized FUS-ALS mouse with a frameshift mutation, which fulfils both criteria: the FUS Delta14 mouse. Heterozygous animals express mutant humanized FUS protein at physiological levels and have adult onset progressive motor neuron loss and denervation of neuromuscular junctions. Additionally, we generated a novel antibody to the unique human frameshift peptide epitope, allowing specific identification of mutant FUS only. Using our new FUSDelta14 ALS mouse-antibody system we show that neurodegeneration occurs in the absence of FUS protein aggregation. FUS mislocalization increases as disease progresses, and mutant FUS accumulates at the rough endoplasmic reticulum. Further, transcriptomic analyses show progressive changes in ribosomal protein levels and mitochondrial function as early disease stages are initiated. Thus, our new physiological mouse model has provided novel insight into the early pathogenesis of FUS-ALS.
- 7 October 2017
- Published by Oxford University Press (OUP) in Brain
- Vol. 140 (11) , 2797-2805
Open AccessHumanized mutant FUS drives progressive motor neuron degeneration without aggregation in ‘FUSDelta14’ knockin mice
Mutations in FUS are causative for amyotrophic lateral sclerosis with a dominant mode of inheritance. In trying to model FUS-amyotrophic lateral sclerosis (ALS) in mouse it is clear that FUS is dosage-sensitive and effects arise from overexpression per se in transgenic strains. Novel models are required that maintain physiological levels of FUS expression and that recapitulate the human disease—with progressive loss of motor neurons in heterozygous animals. Here, we describe a new humanized FUS-ALS mouse with a frameshift mutation, which fulfils both criteria: the FUS Delta14 mouse. Heterozygous animals express mutant humanized FUS protein at physiological levels and have adult onset progressive motor neuron loss and denervation of neuromuscular junctions. Additionally, we generated a novel antibody to the unique human frameshift peptide epitope, allowing specific identification of mutant FUS only. Using our new FUSDelta14 ALS mouse-antibody system we show that neurodegeneration occurs in the absence of FUS protein aggregation. FUS mislocalization increases as disease progresses, and mutant FUS accumulates at the rough endoplasmic reticulum. Further, transcriptomic analyses show progressive changes in ribosomal protein levels and mitochondrial function as early disease stages are initiated. Thus, our new physiological mouse model has provided novel insight into the early pathogenesis of FUS-ALS.
- 1 February 2010
- Published by Elsevier in The American Journal of Pathology
- Vol. 176 (2) , 556-562
CNS Elevation of Vascular and Not Mucosal Addressin Cell Adhesion Molecules in Patients with Multiple Sclerosis
- 1 February 2010
- Published by Elsevier in The American Journal of Pathology
- Vol. 176 (2) , 556-562
CNS Elevation of Vascular and Not Mucosal Addressin Cell Adhesion Molecules in Patients with Multiple Sclerosis